Interactions of antitumor triazoloacridinones with DNA

Acta Biochimica Polonica

Volumn 54, Issue 2, 2007, Pages 297-306

  Koba, Marcin ^a,b   Konopa, Jerzy ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Biological activity; DNA intercalation; DNA interstrand crosslinks; Metabolic activation; Structure activity relationship; Triazoloacridinones

Indexed keywords

EID: 34447344511     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2007_3250     Document Type: Article

References (35)

1. Arjunan P, Arora SK, Cholody WM (1993) Structural studies on DNA binding drugs: crystal structure and molecular dynamics studies of triazoloacridinones. Acta Crystallogr B 46: 96-101.
2. Augustin E, Konopa J (1999) Cell cycle and apoptosis induced by antitumor triazoloacridinones in tumor cells. Folia Histochem Cytobiol 37 (Suppl 1): 41.
3. Augustin E, Plocka E, Konopa J (2000) Induction of cell death (apoptosis) by antitumor triazoloacridinones in tumor cells. Drugs Metab Rev 32 (Suppl 1): 33.
4. Augustin E, Mos-Rompa A, Skwarska A, Witkowski JM, Konopa J (2006) Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochem Pharmacol 72: 1668-1679.
5. Benchokroun Y, Coupie J, Larsen AK (1995) Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochem Pharmacol 49: 305-313.
6. Bhuyan BK, Smith KS, Adams EG, Petzold GL, McGovren JP (1992) Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells. Cancer Res 52: 5687-5692.
7. Capranico G, Zunino F, Kohn KW, Pommier Y (1990) Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 29: 562-569.
8. Chaires JB, Dattagupta N, Crothers DM (1982) Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry 21: 3933-3940.
9. Chaires JB, Satyanarayana S, Suh D, Fokt I, Przewloka T, Priebe W (1996) Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry 35: 2047-2053.
10. Cholody WM, Martelli S, Konopa J (1990) 8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. J Med Chem 33: 2852-2856.
11. Cholody WM, Martelli S, Konopa J (1992) Chromophoremodified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem 35: 378-382.
12. Dackiewicz P, Skladanowski A, Konopa J (1995) 32P-postlabelling analysis of adducts formed by mitoxantrone and amentantrone with DNA and homopolydeoxyribonucleotides after enzymatic activation. Chem Biol Interact 98: 153-166.
13. Dziegielewski J, Slusarski B, Konitz A, Skladanowski A, Konopa J (2002) Interaction of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63: 1653-1666.
14. Hazlehurst LA, Krapcho AP, Hacker MP (1995) Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: azaanthracenediones. Cancer Lett 91: 115-124.
15. Isaacs RJ, Harris AL, Hickson ID (1996) Regulation of human topoisomerase IIα gene promoter in confluencearrested cells. J Biol Chem 271: 16741-16747.
16. Johnson RK, Zee-Cheng RK, Lee WW, Acton EM, Henry DW, Cheng CC (1979) Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63: 425-439.
17. Kapuscinski J, Darzynkiewicz Z (1985) Interactions of antitumor agents ametantrone and mitoxantrone (novatrone) with double-stranded DNA. Biochem Pharmacol 34: 4203-4213.
18. Konopa J (1983) Adriamycin and daunomycin induce interstrand DNA cross-links in HeLa S3 cells. Biochem Biophys Res Commun 110: 819-826.
19. Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, Radzikowski C, Konopa J (1994) Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp 42: 414-423.
20. Lee CS, Gibson NW (1993) DNA interstrand cross-links induced by cyclopropylpyrroloindole antitumor agent Bizelesin are reversible upon exposure to alkali. Biochemistry 32: 9108-9114.
21. Lemke K, Poindessous V, Skladanowski A, Larsen AK (2004) The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 66: 1035-1042.
22. Lemke K, Wojciechowski M, Laine W, Bailly C, Colson P, Baginski M, Larsen AK, Skladanowski A (2005) Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridinone C-1305, a topoisomerase II inhibitor with antitumor activity. Nucleic Acids Res 33: 6034-6047.
23. Mazerska Z, Augustin E, Dziegielewski J, Cholody WM, Konopa J (1996) QSAR of acridines. III. Structure-activity relationship for antitumor imidazoacridinones and intercorrelation between in vivo and in vitro tests. Anti-Cancer Drug Des 11: 73-88.
24. Mazerska Z, Zamponi S, Marassi R, Martelli S (1997) Electrochemical oxidation of antitumor imidazoacridinone derivatives and the reference 2-hydroxyacridinone. J Electroanal Chem 427: 71-78.
25. Mazerski J, Muchniewicz K (2000) The intercalation of imidazoacridinones into DNA induces conformational changes in their side chain. Acta Biochim Polon 47: 65-78.
26. Meunier G, De Montauzon D, Bernadou J, Grassy G, Bonnafous M, Cros S, Meunier B (1988) The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies? Mol Pharmacol 33: 93-102.
27. Pawlak K, Matuszkiewicz A, Pawlak JW, Konopa J (1983) The mode of action of cytotoxic and antitumor 1-nitroacridines. I. The 1-nitroacridines do not exert their cytotoxic effects by physicochemical binding with DNA. Chem Biol Interact 43: 131-149.
28. Pawlak K, Pawlak JW, Konopa J (1984) Cytotoxic and antitumor activity of 1-nitroacridines as an after effect of their interstrand DNA crosslinking. Cancer Res 44: 4289-4296.
29. Reinert KE (1991) DNA-helix bending, stiffening, and elongation on ligand binding; analysis for several DNAdrug systems, general viscometric DNA response and stereochemical implications. J Biomol Struc Dynam 9: 331-352.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Nat Cancer Inst 82: 1107-1112.
31. Skladanowski A, Konopa J (1994a) Interstrand DNA crosslinking induced by anthracyclines in tumour cells. Biochem Pharmacol 47: 2269-2278.
32. Skladanowski A, Konopa J (1994b) Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem Pharmacol 47: 2279-2287.
33. Skladanowski A, Larsen AK, Konopa J, Lemke K (1999) Inhibition of DNA topoisomerase II by antitumor triazoloacridinones in vitro and in tumor cells. Proc Am Assoc Cancer Res 40: 681.
34. Suh D, Chaires JB (1995) Criteria for the mode of binding of DNA binding agents. Bioorg Med Chem 3: 723-728.
35. Wȩsierska-Ga̧dek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A (2004) Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res 64: 4487-4497.